Clinical Data Major trial launched to explore GLP-1 benefit in dementia PharmaphorumA $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.NeuroscienceRead full story pharminent July 13, 2026 (Last updated: July 14, 2026) Pharmaphorum A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia. Neuroscience Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: FDA posts new rejection letters days after confirming pauseNext: Germany approves healthcare costs overhaul despite significant pharma opposition Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
